Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
NPJ Precision Oncology
|
November 18, 2024
Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
D Voulgarelis, J V Forment, A Herencia Ropero, et al.
Molecular Cancer Therapeutics
|
June 13, 2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, et al.
Frontiers in Immunology
|
July 29, 2022
Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model
Soumya P Kania, Juliana M F Silva, Oscar J Charles, et al.
Journal of Medicinal Chemistry
|
October 23, 2018
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
Kevin M Foote, J Willem M Nissink, Thomas McGuire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 23, 2019
Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
Lourdes Cucurull-Sanchez, Michael J Chappell, Vijayalakshmi Chelliah, et al.
Clinical Pharmacology and Therapeutics
|
June 23, 2020
Opportunities for Quantitative Translational Modeling in Oncology
James W T Yates, Helen Byrne, Sonya C Chapman, et al.
Drug Discovery Today
|
June 4, 2013
Model-based drug discovery: implementation and impact
Sandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard, James W T Yates, Zhenfan Yang, et al.
Journal of Pharmaceutical Sciences
|
April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets
Patrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
NPJ Precision Oncology
|
November 18, 2024
Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers
D Voulgarelis, J V Forment, A Herencia Ropero, et al.
Molecular Cancer Therapeutics
|
June 13, 2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, et al.
Frontiers in Immunology
|
July 29, 2022
Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model
Soumya P Kania, Juliana M F Silva, Oscar J Charles, et al.
Journal of Medicinal Chemistry
|
October 23, 2018
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
Kevin M Foote, J Willem M Nissink, Thomas McGuire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 31, 2019
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn, Chao-Hua Chiu, Ying Cheng, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 23, 2019
Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
Lourdes Cucurull-Sanchez, Michael J Chappell, Vijayalakshmi Chelliah, et al.
Clinical Pharmacology and Therapeutics
|
June 23, 2020
Opportunities for Quantitative Translational Modeling in Oncology
James W T Yates, Helen Byrne, Sonya C Chapman, et al.
Drug Discovery Today
|
June 4, 2013
Model-based drug discovery: implementation and impact
Sandra A G Visser, Malin Aurell, Rhys D O Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard, James W T Yates, Zhenfan Yang, et al.
Journal of Pharmaceutical Sciences
|
April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets
Patrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Page
of 8